Therefore, STAT3 has been validated as anti-cancer drug target and targeting STAT3 signaling is considered as a novel promising therapeutic strategy for eradication of HCC CSCs [12, 13]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.